FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound represented by formulas (I) or (II), or a pharmaceutically acceptable salt or stereoisomer thereof, which have property of thrombocyte aggregation inhibition. In formulas (I) and (II), R1 is hydroxy or C1-C10-alkoxy, X is N or O, R2 is -(CH2)p-(5–12-member heterocycle)-(CH2)p-C6-C12-aryl, 5–12-member heterocycle, -(CH2)p-NHC(=O)-C6-C12-aryl, -CHR4R5, 5–12-member heteroaryl, C6-C12-aryl, -C6-C12-aryl-O-(5–12-member heteroaryl) or -(CH2)p-(5–12-member heteroaryl), wherein p is integer from 1 to 10, R4 and R5 represent, each independently, C1-C6-alkoxycarbonyl or -CH2-(5–12-member heteroaryl), said heterocycle and heteroaryl can contain from 1 to 3 heteroatoms selected from N, O and S, said aryl is substituted with 1–4 substitutes selected from a group consisting of nitro, nitrile and hydroxy-C1-C6-alkyl, said heterocycle is substituted with 1–4 substitutes selected from a group consisting of halogen and oxo, said heteroaryl is substituted with 1–4 substitutes selected from a group, consisting of oxo, aminocarbonyl, C1-C6-alkyl, C1-C6-alkylaminocarbonyl, hydroxy and hydroxy-C1-C6-alkyl, provided that when R2 is -(CH2)p-(5–12-member heteroaryl), heteroaryl is not pyrazine, indole or pyridine, and when R2 is 5–12-membered heteroaryl, the heteroaryl is not benzothiazole, R3 represents hydrogen, when X is O, R3 does not exist when X is N, X, taken together with R2 and R3, can form 6-member heterocycle containing 1–3 heteroatoms selected from N, wherein said heterocycle can be substituted with C6-C12-aryl or -O-CHR6R7, where R6 and R7 are each independently C6-C12-aryl or 6–10-member heteroaryl containing 1–3 heteroatoms, selected from O, N and S, which are both unsubstituted or substituted with halogen. Invention also relates to specific compounds and a pharmaceutical composition for preventing or treating thrombotic diseases containing said compounds.
EFFECT: disclosed is a compound having thrombocyte aggregation inhibition action, and a salt thereof, and a composition comprising such compounds for preventing or treating thrombotic diseases.
4 cl, 16 tbl, 35 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL HETEROCYCLIC COMPOUNDS AS BRD4 INHIBITORS | 2016 |
|
RU2721120C2 |
| COMPOUND FOR DESTRUCTION OF ANDROGEN RECEPTOR AND ITS PHARMACEUTICAL USE THEREOF | 2021 |
|
RU2817356C1 |
| COMPOUNDS | 2016 |
|
RU2725616C2 |
| NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITING ACTIVITY | 2019 |
|
RU2768755C1 |
| COMPOUNDS CONTAINING A CLEAVABLE LINKER AND METHODS FOR THEIR USE | 2018 |
|
RU2795168C2 |
| SELECTIVE HDAC6 INHIBITORS, THEIR PRODUCTION METHOD AND THEIR APPLICATION | 2018 |
|
RU2772274C2 |
| HETEROCYCLIC COMPOUNDS AND USE THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS | 2016 |
|
RU2714197C2 |
| ANTITUMOUR COMPOUNDS | 2008 |
|
RU2528393C9 |
| ANTITUMORAL COMPOUNDS | 2008 |
|
RU2489429C2 |
| BENZOFURAZAN ANTIMYLOID COMPOUNDS AND METHODS | 2013 |
|
RU2641293C2 |
